{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T01:11:45Z","timestamp":1772500305210,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","ijdp.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.drugpo.2017.05.042","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T08:15:14Z","timestamp":1498119314000},"page":"126-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["DOT-C: A cluster randomised feasibility trial evaluating d irectly o bserved an t i-H C V therapy in a population receiving opioid substitute therapy from community pharmacy"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4772-2388","authenticated-orcid":false,"given":"Andrew","family":"Radley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Tait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2017.05.042_bib0005","first-page":"844","article-title":"Community pharmacy and public health in Great Britain 1937\u20132006: How a phoenix rose from the ashes","volume":"61","author":"Anderson","year":"2007","journal-title":"Journal of Epidemiology and Public Health"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0010","series-title":"London","article-title":"The contribution of community pharmacy to improving the public\u2019s health: Summary report of the literature review 1990\u20132007. Pharmacy Health Link","author":"Anderson","year":"2009"},{"issue":"3","key":"10.1016\/j.drugpo.2017.05.042_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1258\/RSMSMJ.54.3.3","article-title":"Evaluation of a general practice Hepatitis C virus screening intervention","volume":"54","author":"Anderson","year":"2009","journal-title":"Scottish Medical Journal"},{"issue":"36","key":"10.1016\/j.drugpo.2017.05.042_bib0020","doi-asserted-by":"crossref","first-page":"12722","DOI":"10.3748\/wjg.v20.i36.12722","article-title":"Eligibility of persons who inject drugs for treatment of hepatitis C virus infection","volume":"20","author":"Arain","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2288-10-67","article-title":"What is a pilot or feasibility study? A review of current practice and editorial policy","volume":"10","author":"Arain","year":"2010","journal-title":"BMC Medical Research Methodology"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0030","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMoa1009370","article-title":"Outcomes of treatment for hepatitis C virus infection by primary care providers","volume":"364","author":"Arora","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0035","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/jvh.12393","article-title":"Bruneau Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: Room for improvement","volume":"22","author":"Artenie","year":"2015","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0040","doi-asserted-by":"crossref","DOI":"10.1007\/s10654-014-9958-4","article-title":"Targeted hepatitis C antibody testing interventions: A systematic review and meta-analysis","author":"Aspinall","year":"2015","journal-title":"European Journal of Epidemiology"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0045","doi-asserted-by":"crossref","DOI":"10.1007\/s10198-016-0844-8","article-title":"Hepatitis C disease transmission and treatment uptake: Impact on the cost-effectiveness of new direct-acting antiviral therapies","author":"Bennett","year":"2016","journal-title":"European Journal of Health Economics"},{"issue":"5","key":"10.1016\/j.drugpo.2017.05.042_bib0050","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.amepre.2009.02.002","article-title":"How we design feasibility studies","volume":"36","author":"Bowen","year":"2009","journal-title":"American Journal of Preventative Medicine"},{"issue":"5","key":"10.1016\/j.drugpo.2017.05.042_bib0055","doi-asserted-by":"crossref","first-page":"e0126920","DOI":"10.1371\/journal.pone.0126920","article-title":"The undiagnosed chronically infected HCV population i France. Implications for expanded testing recommendations in 2014","volume":"10","author":"Brouard","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0060","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1053\/j.gastro.2012.02.017","article-title":"Non-invasive methods to assess liver disease in patients with hepatitis","volume":"142","author":"Castera","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0065","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.drugpo.2015.05.001","article-title":"The effect of point of care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: A systematic review of the literature","volume":"26","author":"Coats","year":"2015","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0070","series-title":"Reference costs. In Unit costs of health and social care 2015","author":"Curtis","year":"2015"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0075","unstructured":"Dried Blood Spot Testing Guidelines for Hepatitis C virus, Hepatitis B virus and HIV (2012) NHS tayside sexual health and BBV managed care network Dundee http:\/\/www.sexualhealthtayside.org\/HIV_Testing_Guidelines\/HIV_Testing_Guidelines.php."},{"issue":"Suppl. 5","key":"10.1016\/j.drugpo.2017.05.042_bib0080","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1086\/427441","article-title":"Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users","volume":"40","author":"Edlin","year":"2005","journal-title":"Clinical Infectious Disease"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150205","article-title":"Defining feasibility and pilot studies in prepapration for randomised controlled trials: Development of a conceptual framework","author":"Eldridge","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0090","unstructured":"Electronic medicines compendium statement of product characteristics: Harvoni (Gilead). (2017) http:\/\/www.medicines.org.uk\/emc\/medicine\/29471. (Accessed May 2017)."},{"key":"10.1016\/j.drugpo.2017.05.042_bib0095","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11901-013-0179-1","article-title":"Treatment of hepatitis C in HIV patients in the new era of directly-acting antivirals","volume":"12","author":"Fernandez-Montero","year":"2013","journal-title":"Current Hepatitis Reports"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jhep.2016.02.010","article-title":"Optimising HCV treatment \u2014 Moving beyond the cost conundrum","volume":"65","author":"Fox","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0065-2601(06)38002-1","article-title":"Implementation intentions and goal achievement a meta-analysis of effects and processes","volume":"38","author":"Gollwitzer","year":"2006","journal-title":"Advances in Experimental Social Psychology"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2014.01.002","article-title":"Can hepatitis C virus infection be eradicated in people who inject drugs","volume":"104","author":"Grebely","year":"2014","journal-title":"Antiviral Research"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-7517-10-7","article-title":"Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors","volume":"10","author":"Harris","year":"2013","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0120","unstructured":"Hepatitis C annual report progress made, but much more to do. Public Health England. July. https:\/\/www.gov.uk\/government\/news\/hepatitis-c-annual-report-prog-ress-made-but-much-more-to-do. (Accessed December 2016)."},{"issue":"2","key":"10.1016\/j.drugpo.2017.05.042_bib0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1258\/RSMSMJ.51.2.8","article-title":"Hepatitis C virus infection in Scotland: Epidemiological review and public health challenges","volume":"51","author":"Hutchinson","year":"2006","journal-title":"Scottish Medical Journal"},{"issue":"9","key":"10.1016\/j.drugpo.2017.05.042_bib0130","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1592\/phco.2005.25.9.1230","article-title":"Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic","volume":"25","author":"Kolor","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0135","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1038\/ctg.2016.50","article-title":"Hepatitis C treatment and barriers to eradication","volume":"7","author":"Konerman","year":"2016","journal-title":"Clinical and Translational Gastroenterology"},{"issue":"s1","key":"10.1016\/j.drugpo.2017.05.042_bib0140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver International"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/apt.13673","article-title":"Review Article \u2014 Targeting people who inject drugs as a pathway towards hepatitis C eradication","volume":"44","author":"Leask","year":"2016","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0150","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/hep.27736","article-title":"Cost- effectiveness of hepatitis C treatment for patients in early stages of liver disease","volume":"61","author":"Leidner","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0155","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/MEG.0000000000000711","article-title":"Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment","volume":"28","author":"Lewis","year":"2016","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0160","first-page":"10.1371","article-title":"Are interferon-free direct-acting antivirals for the treatment of HCV enough to control the epidemic among people of inject drugs","author":"Lima","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0165","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","article-title":"New protease inhibitors for the treatment of chronic hepatitis C","volume":"156","author":"Liu","year":"2012","journal-title":"Annal of Internal Medicine"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1741-7015-8-63","article-title":"Normalisation process theory: A framework for developing, evaluating and implementing complex interventions","volume":"8","author":"Murray","year":"2010","journal-title":"BMC Medicine"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0175","series-title":"NHS reference costs 2014 to 2015 [database on the Internet]","year":"2015"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0180","unstructured":"NHS Research Authority Research Summary -SuperDOT-C. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02706223. (Accessed November 2016)."},{"key":"10.1016\/j.drugpo.2017.05.042_bib0185","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/liv.12565","article-title":"Barriers to care and treatment for patients with chronic viral hepatitis in Europe: A systematic review","volume":"34","author":"Papatheodoridis","year":"2014","journal-title":"Liver International"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0190","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study","volume":"2","author":"The Polaris HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0195","article-title":"Standing outside the junkie door service users\u2019 experiences of using community pharmacies to access treatment for opioid dependency","author":"Radley","year":"2016","journal-title":"Journal of Public Health"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0200","doi-asserted-by":"crossref","DOI":"10.1136\/flgastro-2016-100776","article-title":"A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the tayside region of Scotland","author":"Radley","year":"2017","journal-title":"Frontline Gastroenterology"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0205","series-title":"Analysing qualitative data","first-page":"173","article-title":"Qualitative data analysis for applied policy research","author":"Richie","year":"1994"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0210","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s13063-016-1501-3","article-title":"Hepatitis C \u2014 Assessment to treatment trial (HepCATT) in primary care: Study protocol for a randomised controlled trial","volume":"17","author":"Roberts","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0215","series-title":"Management of hepatitis C","author":"Scottish Intercollegiate Guidelines Network (SIGN)","year":"2013"},{"issue":"11","key":"10.1016\/j.drugpo.2017.05.042_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11110","article-title":"Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and economicevaluation 1686","volume":"11","author":"Shepherd","year":"2007","journal-title":"Health Technology Assessment"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0225","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple, non-invasive index to predict significant fibrosis in patients with HIV\/HCV co-infection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.drugpo.2017.05.042_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16040","article-title":"Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: A systematic review and economic evaluation","volume":"16","author":"Stevenson","year":"2012","journal-title":"Health Technology Assessment"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001795","article-title":"A public health approach to hepatitis C control in low - and middle -income countries","author":"Suther","year":"2015","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0240","article-title":"Multidisciplinary managed care networks\u2014Life-saving interventions for hepatitis C patients","author":"Tait","year":"2016","journal-title":"Journal of Viral Hepatitis"},{"issue":"10","key":"10.1016\/j.drugpo.2017.05.042_bib0245","doi-asserted-by":"crossref","DOI":"10.1377\/hlthaff.2014.1193","article-title":"Broad hepatitis C treatment scenarios return substantial health gains, but capacity is a concern","volume":"34","author":"Van Nuys","year":"2014","journal-title":"Health Affairs"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142770","article-title":"The cascade of care for an Australian community based hepatiis C treatment service","author":"Wade","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0255","first-page":"2","article-title":"A systematic review of community based hepatitis C treatment","volume":"20","author":"Wade","year":"2016","journal-title":"BMC Infectious Diseases"},{"key":"10.1016\/j.drugpo.2017.05.042_bib0260","doi-asserted-by":"crossref","first-page":"e103345","DOI":"10.1371\/journal.pone.0103345","article-title":"Hepatitis C virus infection epidemiology among people who inject drugs in Europe: A systematic review of data for scaling up treatment and prevention","volume":"7","author":"Wiessing","year":"2014","journal-title":"PLOS One"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395917301469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395917301469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T10:52:09Z","timestamp":1569495129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395917301469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":52,"alternative-id":["S0955395917301469"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.042","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}